Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Bone Marrow Protective Effect of Trilaciclib in Postoperative CCRT for LA-HNSCC — Stella

Home/Head and Neck Cancer Squamous Cell Carcinoma/Bone Marrow Protective Effect of Trilaciclib in Postoperative CCRT for LA-HNSCC

View on ClinicalTrials.gov

Recruiting

Back to Head and Neck Cancer Squamous Cell Carcinoma trials

Bone Marrow Protective Effect of Trilaciclib in Postoperative CCRT for LA-HNSCC

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Hunan Cancer hospital, Changsha, Hunan

Key details

Phase

Safety & dosing

Sponsor

Hunan Cancer Hospital

Enrollment target

~30 participants

Started

December 2024

Primary completion

September 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 70 Years

Last updated December 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.